#Petrol #Rupee #IL&FS

Receive Free News and Updates

SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD OCT 05
MCX SILVER DEC 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD OCT 05
MCX SILVER DEC 05
MCX CRUDEOIL SEP 19
MCX NATURALGAS SEP 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

Market reverses last week’s gains, Nifty back at 10,300

Asia shares extend slump as global sentiment sours

Oil prices edge up, but set for weekly loss on stock build, trade row

US dollar ends sharply lower against rupee

Oct 11, 2018 12:09 PM IST | Business

Orchid Pharmaceuticals investment was a mistake, says billionaire Adar Poonawalla

No merit in acquiring Panacea Biotech: Adar Poonawalla

Promoter of Panacea Biotech want to continue running the company: Adar Poonawalla

No plans to do anything with stake in Panacea Biotech: Adar Poonawalla

Billionaire Adar Poonawalla, the CEO of one of the world's largest vaccine maker Serum Institute of India, also has regrets. In an interaction with CNBC-TV18, Poonawalla said his biggest mistake was investing in Orchid Pharma.

"Investments in Orchid Pharmaceuticals was perhaps the single mistake we have ever made," said Adar Poonawalla on Thursday.

Adar's father Cyrus Poonawalla and his affiliated firms had acquired around 14 percent stake in Orchid over a period of time. Cyrus had later filed a Company Petition alleging certain acts of oppression and mismanagement in the affairs of Orchid Pharma .

When asked about acquiring Orchid, he said, “We tried to but we had issues with the existing CEO and promoter and that didn’t work out.”

“The debt that they kept taking was without anyone’s consent and they sort of went further into a mess. We just now are getting out of it at whatever value we can,” he said.

Talking about his investments and tie-ups with companies in the listed space, Adar Poonawala said his nearly 15 percent stake in Panacea Biotech is just strategic while tie-up with Cipla is only limited to South Africa.

On the business front, Poonawala said, “We are going to stick to making vaccines and at the most diversify into our new NBFC that we have formed to enter the financial services area.”

Have you signed up for Primo, our daily newsletter? It has all the stories and data on the market, business, economy and tech that you need to know.

Published Date: Oct 11th, 2018 09:16 AM | Updated Date: Oct 11, 2018 12:09 PM IST

You May Also Like

GoAir offers discounted fares starting from Rs 1,499 for travel between November 5 and January 31

GoAir offers discounted fares starting from Rs 1,499 for travel between November 5 and January 31

ICICI Securities' H1FY19 PAT up 8% at Rs 268 crore

ICICI Securities' H1FY19 PAT up 8% at Rs 268 crore

US likely to tighten norms for granting H1-B visa

US likely to tighten norms for granting H1-B visa

Trending on CNBC-TV18

Live TV

recommended for you